Uncategorised

Edinburgh Molecular Imaging Appoints Bernhard Sixt as new Chief Executive Officer

 Edinburgh Molecular Imaging Appoints Bernhard Sixt as new Chief Executive Officer

Seasoned CEO with 30 years’ experience in the healthcare industry

Edinburgh, United Kingdom – 8 November 2018 – Edinburgh Molecular Imaging (EM Imaging), the optical molecular imaging company, today announces the appointment of Dr Bernhard Sixt as Chief Executive Officer, effective immediately.

Dr Sixt has 30 years of healthcare industry experience in the development and commercialisation of laboratory services, in vivo and in vitro diagnostics, and pharmaceuticals for industry leaders such as Amersham (now part of GE Healthcare) and Nycomed Pharma (now part of Takeda).  Since leaving Amersham, Bernhard has led several companies. He is a co‑founder of Agendia and served as its CEO from 2003 until 2011 and in 2005 founded Ipotuba, a pioneer for addressing the emerging need for pharmaceutical cryo-logistics. He also led ImmunID, an innovator in precision immuno-oncology, from 2013 until 2016.  Dr Sixt holds a Master of Science degree in Biochemistry and Chemistry from Ludwig Maximilians University (LMU) and a PhD from the Technical University (TU), both in Munich, Germany.

Roy Davis, Chairman of the Board of EM Imaging, said: “We are very pleased to have attracted someone of Bernhard’s calibre and I warmly welcome him to EM Imaging. Bernhard’s proven track record and experience in leading and growing companies will be invaluable in taking EM Imaging on its next stage of development.

“The board would also like to thank Ian Wilson, a former Amersham colleague of Bernhard, for his contribution in building and leading EM Imaging to its current stage.”

Bernhard Sixt, Chief Executive Officer of EM Imaging, commented: “Throughout my industry career I have always been excited by the potential that optical imaging modality offers.  I am very pleased to join EM Imaging which has the opportunity to maximise the potential offered by advanced optical imaging.  Our lead product, EMI-137, offers a “real time in situ pathology vision” to physicians and surgeons and has the potential for improved cancer detection. It has been safely administered to 69 patients so far demonstrating encouraging data and in a phase 1/2a colonoscopy study demonstrated a 17% increase in cancer lesion detection compared to standard colonoscopy, and increased detection of high risk lesions.  Currently EMI-137 is also being trialled in several other cancer indications.”

ENDS

 

Further information: 

Edinburgh Molecular Imaging

Bernhard Sixt, CEO:

media@emimaging.com

Tel: +131 (0) 658 5308

@edinimage #CRCcure 

Optimum Strategic Communications

Mary Clark, Supriya Mathur

Tel: +44 (0) 203 950 9144

healthcare@optimumcomms.com 

Notes for Editors: 

About Edinburgh Molecular Imaging

EM Imaging’s highly novel molecular imaging technology platform targets disease detection in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue.  With a portfolio focused on development and commercialisation, the company’s optical imaging agents see disease in the body in real time, and help clinicians make time-critical diagnostic and treatment decisions.

EM Imaging’s “SMART” optical agents visualise pathology in vivo by lighting up cells, enzymes and receptors present in disease, reducing the time to diagnose patients from days to seconds, enabling point of care treatment selection and early intervention.  For more information, please visit www.emimaging.com.

The company was formed in 2014 by lead investor Epidarex Capital, a venture capital firm specialising in early stage life science investments.  For more information, please visit www.epidarex.com.

About Optical imaging

Optical imaging is a technique for non-invasively looking inside the body, as is done, for example, with x-rays.  Unlike x-rays, which use ionizing radiation, optical imaging uses visible light and the special properties of photons to obtain detailed images of organs and tissues as well as smaller structures including cells.

adminEdinburgh Molecular Imaging Appoints Bernhard Sixt as new Chief Executive Officer
read more

Edinburgh Molecular Imaging Ltd Appoints New Chairman

EDINBURGH, Scotland, October 29, 2018

Roy Davis appointed as Non-Executive Chairman

– Current Chair John Jeans to continue as Non-Executive Director

Edinburgh Molecular Imaging Ltd (EM Imaging), the clinical phase biotechnology company focused on enabling image-guided therapy, announces the appointment of Roy Davis as non-executive Chairman with immediate effect. John Jeans, who has served as non-executive Chairman since August 2015, will remain on the Board of EM Imaging as a non-executive director.

Mr Davis is currently Chairman of Medica Group plc (the UK’s leading tele-radiology company). He was formerly CEO of Optos Plc, a leading retinal imaging manufacturer from 2008 to 2015 until its sale to Nikon for $400 million in 2014; he continues to be an advisor to Nikon. Prior to this, Mr Davis was CEO of Gyrus Group plc, a leading medical device company focused on minimally invasive surgery and visualisation until it was acquired by Olympus in 2008 for approximately $2 billion.

Mr Davis has over 30 years of operational expertise and strategic consulting experience and holds a mechanical engineering degree, with honours, from Southampton University and an MBA from the London Business School.

Commenting on the appointment, John Jeans said:

I am delighted to welcome Roy to the Board. Given his extensive experience in healthcare and diagnostics, he is a very valuable addition to the Company. Additionally, his leadership skills and deep expertise in medical technology will be central to EM Imaging in bringing its highly novel optical imaging technology to the forefront of the global molecular imaging market. I am pleased to continue to stay on as Director and support Roy, the management team and Board at this exciting stage of the companys growth.

Roy Davis, incoming Non-Executive Chairman of EM Imaging Ltd., said:

The team at EM Imaging has made great progress in establishing a strong portfolio of optical imaging opportunities. I am excited to have this opportunity to contribute to the next phase of the Companys development.

Liz Roper, Partner Epidarex Capital and Board Director, EM Imaging Ltd., said:

We are very pleased to have Roy join as Chair of the Board of EM Imaging, bringing his significant expertise and leadership at a pivotal time in the Companys development . We would like thank John for his significant contribution to the early growth and success of EM Imaging and look forward to working with both Roy and John in continuing to build a leading company in next-generation, optical imaging.

About Edinburgh Molecular Imaging
EM Imaging’s highly novel molecular imaging technology platform targets disease detection in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. With a portfolio focused on development and commercialisation, the company’s optical imaging agents see disease in the body in real time, and help clinicians make time-critical diagnostic and treatment decisions.
EM Imaging’s “SMART” optical agents visualise pathology in vivo by lighting up cells, enzymes and receptors present in disease, reducing the time to diagnose patients from days to seconds, enabling point of care treatment selection and early intervention. For more information, please visit www.emimaging.com.
The company was formed in 2014 by lead investor Epidarex Capital, a venture capital firm specialising in early stage, life science investments. For more information, please visit www.epidarex.com.

About Optical imaging
Optical imaging is a technique for non-invasively looking inside the body, as is done, for example, with x-rays. Unlike x-rays, which use ionizing radiation, optical imaging uses visible light and the special properties of photons to obtain detailed images of organs and tissues as well as smaller structures including cells.

Further information:

Edinburgh Molecular Imaging
Barry Knight, CFO
Email: media@edinimage.com
Tel: +131-(0)-658-5308 / +44-(0)-7967-588463
@edinimage #CRCcure

adminEdinburgh Molecular Imaging Ltd Appoints New Chairman
read more

EDINBURGH MOLECULAR IMAGING ANNOUNCE BOWEL CANCER UK AND BEATING BOWEL CANCER AS CHARITY PARTNER

Bowel Cancer UK and Beating Bowel Cancer announced as Edinburgh Molecular (EM) Imaging’s Charity partner.

EM Imaging, based in Edinburgh, is partnering with Bowel Cancer UK and Beating Bowel Cancer to raise funds for the charity and increase awareness of Scotland’s second biggest cancer killer. The clinical phase biotechnology company focuses on enabling image guided therapy.

The company’s molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue.

Emma McGeever, Scotland Fundraising Manager at Bowel Cancer UK and Beating Bowel Cancer, said: “We are absolutely delighted to be chosen as EM Imaging’s Charity partner. Bowel cancer is Scotland’s third most common cancer and without the amazing support from organisations like EM Imaging we couldn’t continue to fund the highest quality research and essential information and support services that will save lives from bowel cancer.”

John Jeans, Chairman of the Board at EM Imaging Ltd., said: “It is with great pleasure that EM Imaging will be working with Bowel Cancer UK and Beating Bowel Cancer to help raise funds for, and awareness of, this devastating disease. We are already looking forward to our first fund raising events this year with EM Imaging employees participating in #RowAMarathon in June and the Edinburgh Half Marathon. EM Imaging’s mission to help improve patient outcomes in bowel cancer can only be helped by working with such inspiring partners.”

ENDS

For more information and interviews contact Emily.Stallard@bowelcanceruk.org.uk or call 0207 940 1760 / 0755 312 1454

Follow us on social media: Twitter Bowel Cancer UK / Beating Bowel Cancer and Facebook charityBCUK / BeatingBC

Notes to editors

 

About Bowel Cancer UK and Beating Bowel Cancer
Bowel Cancer UK and Beating Bowel Cancer is the UK’s leading bowel cancer charity. We are determined to save lives, improve the quality of life and support all those affected by bowel cancer. We enable and fund research, provide information and support to patients and their families, educate the public and professionals about the disease and campaign for early diagnosis and best treatment and care for all.


About bowel cancer

Bowel cancer is the fourth most common cancer in the UK and the second biggest cancer killer, affecting both men and women. Every 15 minutes in the UK someone is diagnosed with bowel cancer. That’s almost 42,000 people every year.

Bowel cancer is treatable and curable especially if diagnosed early. Nearly everyone diagnosed at the earliest stage will survive bowel cancer. However, this drops significantly as the disease develops. Early diagnosis really does save lives.

 

The symptoms of bowel cancer can include:

  • Bleeding from your bottom and/or blood in your poo
  • A persistent and unexplained change in bowel habit
  • Unexplained weight loss
  • Extreme tiredness for no obvious reason
  • A pain or lump in your tummy

 

Most people with these symptoms don’t have bowel cancer. Other health problems can cause similar symptoms. If you have one or more of these, or if things just don’t feel right, see your GP.

  • Extreme tiredness for no obvious reason
  • Unexplained weight loss
  • A pain or lump in your tummy

 

Most people with these symptoms don’t have bowel cancer. Other health problems can cause similar symptoms. But if you have one or more of these, or if things just don’t feel right, go to see your GP.

adminEDINBURGH MOLECULAR IMAGING ANNOUNCE BOWEL CANCER UK AND BEATING BOWEL CANCER AS CHARITY PARTNER
read more

EM Imaging in the News

The EM Imaging team hosted Paul Wheelhouse MSP, Minister for Business, Innovation and Energy at our laboratories and offices at Edinburgh Bioquarter. We took the opportunity to explain the value of being based near world leading clinicians who can help us drive our products through clinical trials and to market. We also used this opportunity to campaign for Government and NHS support to drive adoption of our technology within Scotland.

Link to news article http://www.bbc.co.uk/news/uk-scotland-38829002

 

adminEM Imaging in the News
read more

Biotech Showcase

biotech-showcase

Our CEO Ian Wilson will be at the Biotech Showcase on January 9–11 in San Francisco. Contact him through the partnering system to arrange a meeting.

adminBiotech Showcase
read more

EDINBURGH MOLECULAR IMAGING ARE PART OF A EPSRC FUNDED CONSORTIUM

Edinburgh Molecular Imaging is part of an EPSRC funded consortium, led by Dr Jon Shephard of Heriot-Watt University in collaboration with Professor David Jayne from the University of Leeds to develop a revolutionary new bowel cancer surgery tool that will enable surgeons to carry out operations with far greater precision.

adminEDINBURGH MOLECULAR IMAGING ARE PART OF A EPSRC FUNDED CONSORTIUM
read more

EM Imaging at EIE16

adminEM Imaging at EIE16
read more

Edinburgh Molecular imaging Ltd awarded Innovate UK grant to qualify the role of EMI-137 in colorectal cancer lesion detection

Edinburgh Molecular imaging Ltd (EM Imaging) announced today that the company has received a SBRI Stratified Medicine Connecting the UK Infrastructure Phase I grant from the UK’s innovation agency, Innovate UK. The SBRI grant aims to accelerate and increase the development and adoption of innovative diagnostic tools in order to offer better targeted treatment to patients within the UK healthcare system. It also aims to demonstrate the benefits of companies working within the UK ‘enabling infrastructure’, which is made up of specialist organisations that can help companies understand healthcare needs, and design, evaluate and deliver their products and services into the NHS.

 

EM Imaging is partnering with the National Institute for Health Research Colorectal Therapies Healthcare Technology Co-operative (NIHR Colorectal Therapies HTC) and the NIHR Diagnostic Evidence Co-operative Leeds (NIHR DEC Leeds), both based at the Leeds Teaching Hospitals NHS Trust to qualify the potential role of the novel optical imaging agent EMI-137 for the improved detection of colorectal (CRC) lesion during colonoscopy.

 

Phase I of the SBRI project will provide an initial demonstration of the clinical and economic utility of EMI-137, thereby providing key inputs for the design of a potential follow-on Phase II SBRI and future clinical studies to be undertaken by EM imaging.

 

Ian Wilson, CEO of EMI, commented: “EM Imaging are extremely grateful to Innovate UK for their award to formalise the health economic value of EMI-137. The detection of flat, smaller non-polypoid lesion is problematic, which cannot be detected by conventional imaging. EMI-137 potentially addresses this major unmet medical need, by combining targeted molecular probes and advanced imaging technology to improve polyp detection. The whole EM Imaging team is extremely motivated to complete this product’s development and get it into the hands of physicians in order to benefit patients.”

 

Professor David Jayne, Professor of Surgery at the University of Leeds and Clinical Director of the NIHR Colorectal Therapies HTC in Leeds said: “We are delighted to be working closely with EM Imaging on an Innovate UK-funded project to evaluate an exciting new technique for detecting early bowel tumours. EM Imaging’s novel fluorescent molecular probe can help doctors detect more bowel tumours during colonoscopy. This will allow the tumours to be removed before they get to an advanced stage and therefore improve the outlook for the many patients who suffer from this condition.”

 

About EMI-137

GE-137, a water-soluble probe consisting of a 26–amino acid cyclic peptide that binds the human tyrosine kinase c-Met conjugated to a fluorescent cyanine dye. Intravenous administration of GE-137 leads to its accumulation specifically in c-Met–expressing tumours, and it is safe and well tolerated in humans. Fluorescence colonoscopy in patients receiving intravenous GE-137 enabled visualization of all neoplastic polyps that were visible with white light, as well as an additional previously missed polyps that were not visible with white light. The first-in-human pilot study, published in Nature Medicine shows that molecular imaging using an intravenous fluorescent agent specific for c-Met is feasible and safe, and that it may enable the detection of polyps missed by other techniques.

 

About Edinburgh Molecular Imaging

EM imaging is a diagnostics company, with a comprehensive R&D portfolio, focused on the development and commercialisation of Optical Imaging agents. The EM Imaging team is made up of academic and industry experts in the field of imaging, chemistry, clinical development, regulatory affairs and commercialisation of in vivo diagnostic imaging products.

 

About NIHR’s Colorectal Therapies Healthcare Technology Co-operative and Diagnostic Evidence Co-operative Leeds

The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. The NIHR is the research arm of the NHS. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government’s strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, visit the NIHR website (www.nihr.ac.uk).

The National Institute for Health Research has funded four Diagnostic Evidence Co-operatives (DECs) to help generate information on the clinical and cost-effectiveness of in vitro diagnostic devices which are important in helping to improve the way diseases are diagnosed. This will help patients access the most appropriate treatments more quickly and help the NHS make the best use of its resources.

The Academic Unit of Health Economics (AUHE) at the University of Leeds specialises in evaluations of diagnostic tests and works collaboratively with the NIHR DEC Leeds.

 

The NIHR Colorectal Therapies HTC is a national network that provides expertise in biomedical science, clinical application and commercialisation to advance the care of patients with colorectal diseases. Through a structured and collaborative approach the HTC defines clinical areas in need of innovation and develops novel solutions that are progressed to clinical practice.

 
Further information:

 

Edinburgh Molecular Imaging

 

info@emimaging.com

www.emimaging.com

adminEdinburgh Molecular imaging Ltd awarded Innovate UK grant to qualify the role of EMI-137 in colorectal cancer lesion detection
read more

EM Imaging finalist at Pitch@Palace

EM Imaging has been selected  as one of the 14 teams that will Pitch on Monday 7th March, 2016 at St. James’s Palace. In addition, there will be a Peoples Choice vote and we would appreciate if our followers could vote for us at the following link.

ow.ly/YI6dN

 

 

 

adminEM Imaging finalist at Pitch@Palace
read more

Edinburgh Molecular Imaging to Pitch@Palace

Edinburgh Molecular Imaging have been announced as finalists at the Duke of York’s ‘Pitch at the Palace’ competition, which is designed to help entrepreneurs develop their business ideas. The team  will pitch to HRH Duke of York and 300 business people at St James’s Palace on 7 March.

adminEdinburgh Molecular Imaging to Pitch@Palace
read more